BR112023023890A2 - Ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos - Google Patents

Ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos

Info

Publication number
BR112023023890A2
BR112023023890A2 BR112023023890A BR112023023890A BR112023023890A2 BR 112023023890 A2 BR112023023890 A2 BR 112023023890A2 BR 112023023890 A BR112023023890 A BR 112023023890A BR 112023023890 A BR112023023890 A BR 112023023890A BR 112023023890 A2 BR112023023890 A2 BR 112023023890A2
Authority
BR
Brazil
Prior art keywords
precursors
radiopharmaceutical
sst
somatostatin receptor
linders
Prior art date
Application number
BR112023023890A
Other languages
English (en)
Inventor
Hans-Jürgen Wester
Mara Parzinger
Frederik Fahnauer Markus
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of BR112023023890A2 publication Critical patent/BR112023023890A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos. são fornecidos compostos de ligante de receptor de sst inovadores adequados para imageamento e/ou tratamento de tumores neuroendócrinos. estes compostos de ligante de receptor de sst são compostos por um motivo de ligação sst, um grupo aceitador de fluoreto de silício que pode ser marcado com 18f por troca isotópica de 19f por 18f ou que é marcado com 18f, um grupo quelante adequado para formar um quelato com um cátion radioativo ou não radioativo e uma unidade de aminoácido hidrofílica ou uma sequência de tais unidades.
BR112023023890A 2021-05-14 2022-05-12 Ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos BR112023023890A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21173849 2021-05-14
PCT/EP2022/062985 WO2022238553A1 (en) 2021-05-14 2022-05-12 Radiopharmaceutical somatostatin receptor ligands and precursors thereof

Publications (1)

Publication Number Publication Date
BR112023023890A2 true BR112023023890A2 (pt) 2024-01-30

Family

ID=75936725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023890A BR112023023890A2 (pt) 2021-05-14 2022-05-12 Ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos

Country Status (9)

Country Link
EP (1) EP4337270A1 (pt)
JP (1) JP2024517971A (pt)
KR (1) KR20240008341A (pt)
CN (1) CN117320759A (pt)
AU (1) AU2022273184A1 (pt)
BR (1) BR112023023890A2 (pt)
CA (1) CA3214915A1 (pt)
IL (1) IL308414A (pt)
WO (1) WO2022238553A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117777296B (zh) * 2024-02-28 2024-05-28 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132700B (zh) * 2017-07-28 2022-12-13 慕尼黑工业大学 双模放射性示踪剂与治疗剂

Also Published As

Publication number Publication date
EP4337270A1 (en) 2024-03-20
KR20240008341A (ko) 2024-01-18
IL308414A (en) 2024-01-01
JP2024517971A (ja) 2024-04-23
AU2022273184A1 (en) 2023-10-12
CA3214915A1 (en) 2022-11-17
WO2022238553A1 (en) 2022-11-17
CN117320759A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
BR112023023890A2 (pt) Ligantes radiofarmacêuticos de receptor de somatostatina e precursores dos mesmos
Zischler et al. Alcohol‐enhanced Cu‐mediated radiofluorination
MX2023007914A (es) Marcador radioactivo de modo dual y terapeuticos.
RU2742660C2 (ru) Конъюгированные бисфосфонаты для диагностики и терапии заболеваний костей
BR112016022785A8 (pt) composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto
WO2016065145A2 (en) Psma targeted reversed carbamates and methods of use thereof
EA202192045A1 (ru) Средства для диагностической визуализации ракового заболевания
SI9620044B (sl) Ternarni radiofarmacevtski kompleksi
JP2017530109A5 (ja) 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護のための組成物及びキット
EA201892668A1 (ru) Tc-EDDA/HYNIC-iPSMA В КАЧЕСТВЕ РАДИОФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА ДЛЯ ОБНАРУЖЕНИЯ СВЕРХЭКСПРЕССИИ ПРОСТАТСПЕЦИФИЧЕСКОГО МЕМБРАННОГО АНТИГЕНА
WO2018222778A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
BR112022001600A2 (pt) Regimes de dosagem para inibidores do fator d de complemento oral
Bratteby et al. Aliphatic 18F‐Radiofluorination: Recent Advances in the Labeling of Base‐Sensitive Substrates
Zhang et al. Enantioselective Hydrosilylation of β, β‐Disubstituted Enamides to Construct α‐Aminosilanes with Vicinal Stereocenters
Zlatopolskiy et al. Minimalist approach meets green chemistry: synthesis of 18F‐labeled (hetero) aromatics in pure ethanol
Levason et al. [AlCl 3 (BnMe 2-tacn)]–a new metal chelate scaffold for radiofluorination by Cl/F exchange
WO2010036140A1 (ru) Металлокомплексы, способ их получения, радиофармацевтические средства на их основе
Kawakita et al. Interactions between Elongation Factor Tu• Guanosine Triphosphate and Ribosomes and the Role of Ribosome-bound Transfer RNA in Guanosine Triphosphatase Reaction
He et al. Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18 F] FBPA using aryldiboron precursors
Valls-Ferrusola et al. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT
CN103930388A (zh) 新型谷氨酸酯衍生物的前体
Lindner et al. Azeotropic drying free [18 F] FDG synthesis and its application to a lab-on-chip platform
EP2981531A1 (en) [11 c]and [18f]labeled 1,3-diphenyl-5-(pyrimidin-2-yl)-pyridin-2(1 h)-one derivatives and their use for pet imaging of the ampa receptor
JP2020504670A (ja) 固相コンディショニング
Miyoshi et al. Application of the Pfeiffer effect to the assignment of absolute configurations to octahedral metal complexes of the type cis-[M (diamine) 2 (X)(Y)] n+ and related complexes